Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3)

 MK12_HUMAN              Reviewed;         367 AA.
P53778; Q14260; Q6IC53; Q99588; Q99672;
01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
15-JUL-1998, sequence version 3.
27-SEP-2017, entry version 190.
RecName: Full=Mitogen-activated protein kinase 12;
Short=MAP kinase 12;
Short=MAPK 12;
EC=2.7.11.24 {ECO:0000269|PubMed:10212242};
AltName: Full=Extracellular signal-regulated kinase 6;
Short=ERK-6;
AltName: Full=Mitogen-activated protein kinase p38 gamma;
Short=MAP kinase p38 gamma;
AltName: Full=Stress-activated protein kinase 3;
Name=MAPK12; Synonyms=ERK6, SAPK3;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
AND MUTAGENESIS OF TYR-185.
TISSUE=Skeletal muscle;
PubMed=8633070; DOI=10.1073/pnas.93.9.4355;
Lechner C., Zahalka M.A., Giot J.-F., Moeller N.P.H., Ullrich A.;
"ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast
differentiation.";
Proc. Natl. Acad. Sci. U.S.A. 93:4355-4359(1996).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
TISSUE=Skeletal muscle;
PubMed=9169156; DOI=10.1006/geno.1997.4633;
Goedert M., Hasegawa J., Craxton M., Leversha M.A., Clegg S.;
"Assignment of the human stress-activated protein kinase-3 gene
(SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization.";
Genomics 41:501-502(1997).
[3]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=8920915; DOI=10.1006/bbrc.1996.1662;
Li Z., Jiang Y., Ulevitch R.J., Han J.;
"The primary structure of p38 gamma: a new member of p38 group of MAP
kinases.";
Biochem. Biophys. Res. Commun. 228:334-340(1996).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
MET-103.
PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
Beare D.M., Dunham I.;
"A genome annotation-driven approach to cloning the human ORFeome.";
Genome Biol. 5:R84.1-R84.11(2004).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=10591208; DOI=10.1038/990031;
Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
Khan A.S., Lane L., Tilahun Y., Wright H.;
"The DNA sequence of human chromosome 22.";
Nature 402:489-495(1999).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
TISSUE=Pancreas;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[7]
FUNCTION IN PHOSPHORYLATION OF ATF2; ELK1 AND MBP, AND ENZYME
REGULATION.
PubMed=9430721; DOI=10.1074/jbc.273.3.1741;
Enslen H., Raingeaud J., Davis R.J.;
"Selective activation of p38 mitogen-activated protein (MAP) kinase
isoforms by the MAP kinase kinases MKK3 and MKK6.";
J. Biol. Chem. 273:1741-1748(1998).
[8]
INTERACTION WITH SNTA1, ENZYME REGULATION, BIOPHYSICOCHEMICAL
PROPERTIES, AND CATALYTIC ACTIVITY.
PubMed=10212242; DOI=10.1074/jbc.274.18.12626;
Hasegawa M., Cuenda A., Spillantini M.G., Thomas G.M.,
Buee-Scherrer V., Cohen P., Goedert M.;
"Stress-activated protein kinase-3 interacts with the PDZ domain of
alpha1-syntrophin. A mechanism for specific substrate recognition.";
J. Biol. Chem. 274:12626-12631(1999).
[9]
PHOSPHORYLATION BY MAP2K6/MKK6.
PubMed=11010976; DOI=10.1074/jbc.M007835200;
Alonso G., Ambrosino C., Jones M., Nebreda A.R.;
"Differential activation of p38 mitogen-activated protein kinase
isoforms depending on signal strength.";
J. Biol. Chem. 275:40641-40648(2000).
[10]
FUNCTION IN REGULATION OF THE G2 CHECKPOINT.
PubMed=10848581; DOI=10.1128/MCB.20.13.4543-4552.2000;
Wang X., McGowan C.H., Zhao M., He L., Downey J.S., Fearns C.,
Wang Y., Huang S., Han J.;
"Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced
cell cycle arrest.";
Mol. Cell. Biol. 20:4543-4552(2000).
[11]
SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
TISSUE=Heart;
PubMed=11991731; DOI=10.1006/jmcc.2001.1523;
Court N.W., dos Remedios C.G., Cordell J., Bogoyevitch M.A.;
"Cardiac expression and subcellular localization of the p38 mitogen-
activated protein kinase member, stress-activated protein kinase-3
(SAPK3).";
J. Mol. Cell. Cardiol. 34:413-426(2002).
[12]
MUTAGENESIS, SUBCELLULAR LOCATION, AND INTERACTION WITH SH3BP5.
PubMed=12167088; DOI=10.1042/BJ20020553;
Wiltshire C., Matsushita M., Tsukada S., Gillespie D.A., May G.H.;
"A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab
(SH3BP5), associates with mitochondria.";
Biochem. J. 367:577-585(2002).
[13]
FUNCTION.
PubMed=14592936; DOI=10.1152/ajpregu.00563.2003;
Ho R.C., Alcazar O., Fujii N., Hirshman M.F., Goodyear L.J.;
"p38gamma MAPK regulation of glucose transporter expression and
glucose uptake in L6 myotubes and mouse skeletal muscle.";
Am. J. Physiol. 286:R342-R349(2004).
[14]
MUTAGENESIS OF ASP-179 AND PHE-330.
PubMed=15284239; DOI=10.1074/jbc.M404595200;
Diskin R., Askari N., Capone R., Engelberg D., Livnah O.;
"Active mutants of the human p38alpha mitogen-activated protein
kinase.";
J. Biol. Chem. 279:47040-47049(2004).
[15]
FUNCTION, INDUCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND
UBIQUITINATION.
PubMed=17724032; DOI=10.1074/jbc.M703857200;
Qi X., Pohl N.M., Loesch M., Hou S., Li R., Qin J.Z., Cuenda A.,
Chen G.;
"p38alpha antagonizes p38gamma activity through c-Jun-dependent
ubiquitin-proteasome pathways in regulating Ras transformation and
stress response.";
J. Biol. Chem. 282:31398-31408(2007).
[16]
FUNCTION IN PHOSPHORYLATION OF DLG1.
PubMed=20605917; DOI=10.1242/jcs.066514;
Sabio G., Cerezo-Guisado M.I., Del Reino P., Inesta-Vaquera F.A.,
Rousseau S., Arthur J.S., Campbell D.G., Centeno F., Cuenda A.;
"p38gamma regulates interaction of nuclear PSF and RNA with the
tumour-suppressor hDlg in response to osmotic shock.";
J. Cell Sci. 123:2596-2604(2010).
[17]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=21269460; DOI=10.1186/1752-0509-5-17;
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
"Initial characterization of the human central proteome.";
BMC Syst. Biol. 5:17-17(2011).
[18]
FUNCTION.
PubMed=21172807; DOI=10.1242/jcs.068254;
Kukkonen-Macchi A., Sicora O., Kaczynska K., Oetken-Lindholm C.,
Pouwels J., Laine L., Kallio M.J.;
"Loss of p38gamma MAPK induces pleiotropic mitotic defects and massive
cell death.";
J. Cell Sci. 124:216-227(2011).
[19]
INVOLVEMENT IN CANCER.
PubMed=21532888; DOI=10.1593/neo.101748;
Meng F., Zhang H., Liu G., Kreike B., Chen W., Sethi S., Miller F.R.,
Wu G.;
"p38gamma mitogen-activated protein kinase contributes to oncogenic
properties maintenance and resistance to poly (ADP-ribose)-polymerase-
1 inhibition in breast cancer.";
Neoplasia 13:472-482(2011).
[20]
REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
PubMed=20626350; DOI=10.1042/BJ20100323;
Cuadrado A., Nebreda A.R.;
"Mechanisms and functions of p38 MAPK signalling.";
Biochem. J. 429:403-417(2010).
[21]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185, AND IDENTIFICATION
BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Erythroleukemia;
PubMed=23186163; DOI=10.1021/pr300630k;
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
Mohammed S.;
"Toward a comprehensive characterization of a human cancer cell
phosphoproteome.";
J. Proteome Res. 12:260-271(2013).
[22]
X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS), COFACTOR, AND SUBUNIT.
PubMed=10508788; DOI=10.1016/S0969-2126(99)80173-7;
Bellon S., Fitzgibbon M.J., Fox T., Hsiao H.M., Wilson K.P.;
"The structure of phosphorylated p38gamma is monomeric and reveals a
conserved activation-loop conformation.";
Structure 7:1057-1065(1999).
[23]
VARIANTS [LARGE SCALE ANALYSIS] MET-103 AND ASN-230.
PubMed=17344846; DOI=10.1038/nature05610;
Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
"Patterns of somatic mutation in human cancer genomes.";
Nature 446:153-158(2007).
-!- FUNCTION: Serine/threonine kinase which acts as an essential
component of the MAP kinase signal transduction pathway. MAPK12 is
one of the four p38 MAPKs which play an important role in the
cascades of cellular responses evoked by extracellular stimuli
such as proinflammatory cytokines or physical stress leading to
direct activation of transcription factors such as ELK1 and ATF2.
Accordingly, p38 MAPKs phosphorylate a broad range of proteins and
it has been estimated that they may have approximately 200 to 300
substrates each. Some of the targets are downstream kinases such
as MAPKAPK2, which are activated through phosphorylation and
further phosphorylate additional targets. Plays a role in myoblast
differentiation and also in the down-regulation of cyclin D1 in
response to hypoxia in adrenal cells suggesting MAPK12 may inhibit
cell proliferation while promoting differentiation. Phosphorylates
DLG1. Following osmotic shock, MAPK12 in the cell nucleus
increases its association with nuclear DLG1, thereby causing
dissociation of DLG1-SFPQ complexes. This function is independent
of its catalytic activity and could affect mRNA processing and/or
gene transcription to aid cell adaptation to osmolarity changes in
the environment. Regulates UV-induced checkpoint signaling and
repair of UV-induced DNA damage and G2 arrest after gamma-
radiation exposure. MAPK12 is involved in the regulation of SLC2A1
expression and basal glucose uptake in L6 myotubes; and negatively
regulates SLC2A4 expression and contraction-mediated glucose
uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is
stimulated by MAPK14 and inhibited by MAPK12, leading to a
distinct AP-1 regulation. MAPK12 is required for the normal
kinetochore localization of PLK1, prevents chromosomal instability
and supports mitotic cell viability. MAPK12-signaling is also
positively regulating the expansion of transient amplifying
myogenic precursor cells during muscle growth and regeneration.
{ECO:0000269|PubMed:10848581, ECO:0000269|PubMed:14592936,
ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:20605917,
ECO:0000269|PubMed:21172807, ECO:0000269|PubMed:8633070,
ECO:0000269|PubMed:9430721}.
-!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
{ECO:0000269|PubMed:10212242}.
-!- COFACTOR:
Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
Evidence={ECO:0000269|PubMed:10508788};
Note=Binds 2 magnesium ions. {ECO:0000269|PubMed:10508788};
-!- ENZYME REGULATION: Activated by phosphorylation on threonine and
tyrosine. MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for the
activation of MAPK12 induced by environmental stress, whereas
MAP2K6/MKK6 is the major MAPK12 activator in response to TNF-
alpha. {ECO:0000269|PubMed:10212242, ECO:0000269|PubMed:9430721}.
-!- BIOPHYSICOCHEMICAL PROPERTIES:
Kinetic parameters:
KM=37 uM for ATP {ECO:0000269|PubMed:10212242};
KM=313 uM for EGFR substrate peptide
{ECO:0000269|PubMed:10212242};
KM=254 uM for GST-ATF2 {ECO:0000269|PubMed:10212242};
-!- SUBUNIT: Monomer. Interacts with the PDZ domain of the syntrophin
SNTA1. Interacts with SH3BP5. Interacts with LIN7C, SCRIB and
SYNJ2BP (By similarity). {ECO:0000250}.
-!- INTERACTION:
Q16512:PKN1; NbExp=2; IntAct=EBI-602406, EBI-602382;
P29074:PTPN4; NbExp=2; IntAct=EBI-602406, EBI-710431;
Q14160:SCRIB; NbExp=3; IntAct=EBI-602406, EBI-357345;
Q8IUQ4:SIAH1; NbExp=3; IntAct=EBI-602406, EBI-747107;
-!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Mitochondrion.
Note=Mitochondrial when associated with SH3BP5. In skeletal muscle
colocalizes with SNTA1 at the neuromuscular junction and
throughout the sarcolemma (By similarity). {ECO:0000250}.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=2;
Name=1;
IsoId=P53778-1; Sequence=Displayed;
Name=2;
IsoId=P53778-2; Sequence=VSP_055224;
Note=No experimental confirmation available.;
-!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle and heart.
{ECO:0000269|PubMed:11991731, ECO:0000269|PubMed:8633070}.
-!- INDUCTION: Expression of MAPK12 is down-regulation by MAPK14
activation. {ECO:0000269|PubMed:17724032}.
-!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
whose phosphorylation activates the MAP kinases.
-!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K3/MKK3
and MAP2K6/MKK6, which activates the enzyme.
{ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:17724032}.
-!- PTM: Ubiquitinated. Ubiquitination leads to degradation by the
proteasome pathway. {ECO:0000269|PubMed:17724032}.
-!- DISEASE: Note=MAPK is overexpressed in highly metastatic breast
cancer cell lines and its expression is preferentially associated
with basal-like and metastatic phenotypes of breast tumor samples.
-!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
Ser/Thr protein kinase family. MAP kinase subfamily.
{ECO:0000305}.
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/MAPK12ID41290ch22q13.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; X79483; CAA55984.1; -; mRNA.
EMBL; Y10487; CAA71511.1; -; mRNA.
EMBL; U66243; AAB40118.1; -; mRNA.
EMBL; CR456515; CAG30401.1; -; mRNA.
EMBL; AL022328; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; BC015741; AAH15741.1; -; mRNA.
CCDS; CCDS14089.1; -. [P53778-1]
CCDS; CCDS77688.1; -. [P53778-2]
PIR; JC5252; JC5252.
PIR; JC6138; JC6138.
RefSeq; NP_001290181.1; NM_001303252.2. [P53778-2]
RefSeq; NP_002960.2; NM_002969.5. [P53778-1]
UniGene; Hs.432642; -.
PDB; 1CM8; X-ray; 2.40 A; A/B=1-367.
PDB; 4QUM; X-ray; 2.52 A; B=182-190.
PDBsum; 1CM8; -.
PDBsum; 4QUM; -.
ProteinModelPortal; P53778; -.
SMR; P53778; -.
BioGrid; 112207; 27.
CORUM; P53778; -.
DIP; DIP-34241N; -.
IntAct; P53778; 14.
MINT; MINT-90266; -.
STRING; 9606.ENSP00000215659; -.
BindingDB; P53778; -.
ChEMBL; CHEMBL4674; -.
DrugBank; DB05403; CEP-1347.
DrugBank; DB05157; KC706.
DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DrugBank; DB02482; Phosphonothreonine.
GuidetoPHARMACOLOGY; 1501; -.
iPTMnet; P53778; -.
PhosphoSitePlus; P53778; -.
BioMuta; MAPK12; -.
DMDM; 2851522; -.
EPD; P53778; -.
MaxQB; P53778; -.
PaxDb; P53778; -.
PeptideAtlas; P53778; -.
PRIDE; P53778; -.
DNASU; 6300; -.
Ensembl; ENST00000215659; ENSP00000215659; ENSG00000188130. [P53778-1]
Ensembl; ENST00000622558; ENSP00000479972; ENSG00000188130. [P53778-2]
GeneID; 6300; -.
KEGG; hsa:6300; -.
UCSC; uc003bkl.2; human. [P53778-1]
CTD; 6300; -.
DisGeNET; 6300; -.
EuPathDB; HostDB:ENSG00000188130.13; -.
GeneCards; MAPK12; -.
HGNC; HGNC:6874; MAPK12.
HPA; CAB025483; -.
HPA; HPA054562; -.
MIM; 602399; gene.
neXtProt; NX_P53778; -.
OpenTargets; ENSG00000188130; -.
PharmGKB; PA30619; -.
eggNOG; KOG0660; Eukaryota.
eggNOG; ENOG410XNY0; LUCA.
GeneTree; ENSGT00550000074271; -.
HOGENOM; HOG000233024; -.
HOVERGEN; HBG014652; -.
InParanoid; P53778; -.
KO; K04441; -.
OMA; HTLFCLR; -.
OrthoDB; EOG091G08QL; -.
PhylomeDB; P53778; -.
TreeFam; TF105100; -.
BRENDA; 2.7.11.24; 2681.
Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
Reactome; R-HSA-171007; p38MAPK events.
Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
Reactome; R-HSA-375170; CDO in myogenesis.
Reactome; R-HSA-376172; DSCAM interactions.
Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
SignaLink; P53778; -.
SIGNOR; P53778; -.
EvolutionaryTrace; P53778; -.
GeneWiki; MAPK12; -.
GenomeRNAi; 6300; -.
PRO; PR:P53778; -.
Proteomes; UP000005640; Chromosome 22.
Bgee; ENSG00000188130; -.
CleanEx; HS_MAPK12; -.
ExpressionAtlas; P53778; baseline and differential.
Genevisible; P53778; HS.
GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
GO; GO:0005829; C:cytosol; TAS:Reactome.
GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
GO; GO:0005634; C:nucleus; IBA:GO_Central.
GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
GO; GO:0007050; P:cell cycle arrest; TAS:ProtInc.
GO; GO:0006975; P:DNA damage induced protein phosphorylation; TAS:ProtInc.
GO; GO:0007517; P:muscle organ development; TAS:ProtInc.
GO; GO:0045445; P:myoblast differentiation; IDA:UniProtKB.
GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
GO; GO:0010952; P:positive regulation of peptidase activity; NAS:ParkinsonsUK-UCL.
GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
GO; GO:0007165; P:signal transduction; TAS:ProtInc.
GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
InterPro; IPR011009; Kinase-like_dom.
InterPro; IPR003527; MAP_kinase_CS.
InterPro; IPR008352; MAPK_p38.
InterPro; IPR000719; Prot_kinase_dom.
InterPro; IPR017441; Protein_kinase_ATP_BS.
Pfam; PF00069; Pkinase; 1.
PRINTS; PR01773; P38MAPKINASE.
SMART; SM00220; S_TKc; 1.
SUPFAM; SSF56112; SSF56112; 1.
PROSITE; PS01351; MAPK; 1.
PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
1: Evidence at protein level;
3D-structure; Alternative splicing; ATP-binding; Cell cycle;
Complete proteome; Cytoplasm; Kinase; Magnesium; Metal-binding;
Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
Polymorphism; Reference proteome; Serine/threonine-protein kinase;
Stress response; Transcription; Transcription regulation; Transferase;
Ubl conjugation.
CHAIN 1 367 Mitogen-activated protein kinase 12.
/FTId=PRO_0000186282.
DOMAIN 27 311 Protein kinase. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
NP_BIND 33 41 ATP. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
MOTIF 183 185 TXY.
ACT_SITE 153 153 Proton acceptor. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
BINDING 56 56 ATP. {ECO:0000255|PROSITE-
ProRule:PRU00159}.
MOD_RES 183 183 Phosphothreonine; by MAP2K3 and MAP2K6.
{ECO:0000250|UniProtKB:Q63538}.
MOD_RES 185 185 Phosphotyrosine.
{ECO:0000244|PubMed:23186163}.
VAR_SEQ 142 151 Missing (in isoform 2).
{ECO:0000303|PubMed:15461802}.
/FTId=VSP_055224.
VARIANT 103 103 T -> M (in dbSNP:rs34422484).
{ECO:0000269|PubMed:15461802,
ECO:0000269|PubMed:17344846}.
/FTId=VAR_042265.
VARIANT 230 230 D -> N (in dbSNP:rs35396905).
{ECO:0000269|PubMed:17344846}.
/FTId=VAR_042266.
VARIANT 244 244 T -> M (in dbSNP:rs2066776).
/FTId=VAR_012002.
MUTAGEN 179 179 D->A: Emulation of the active state.
{ECO:0000269|PubMed:15284239}.
MUTAGEN 185 185 Y->F: Loss of activity.
{ECO:0000269|PubMed:8633070}.
MUTAGEN 330 330 F->S: No effect.
{ECO:0000269|PubMed:15284239}.
CONFLICT 7 7 A -> T (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 70 70 R -> L (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 138 138 L -> M (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 201 202 MR -> IA (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 261 261 Y -> N (in Ref. 3; AAB40118).
{ECO:0000305}.
CONFLICT 297 298 EQ -> DI (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 300 300 V -> L (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 305 305 A -> F (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 307 307 A -> S (in Ref. 1; CAA55984).
{ECO:0000305}.
CONFLICT 332 333 DV -> YF (in Ref. 1; CAA55984).
{ECO:0000305}.
STRAND 17 21 {ECO:0000244|PDB:1CM8}.
STRAND 24 32 {ECO:0000244|PDB:1CM8}.
STRAND 41 46 {ECO:0000244|PDB:1CM8}.
TURN 47 49 {ECO:0000244|PDB:1CM8}.
STRAND 52 57 {ECO:0000244|PDB:1CM8}.
HELIX 65 80 {ECO:0000244|PDB:1CM8}.
STRAND 90 93 {ECO:0000244|PDB:1CM8}.
TURN 99 101 {ECO:0000244|PDB:1CM8}.
STRAND 106 110 {ECO:0000244|PDB:1CM8}.
STRAND 113 115 {ECO:0000244|PDB:1CM8}.
HELIX 116 122 {ECO:0000244|PDB:1CM8}.
HELIX 127 146 {ECO:0000244|PDB:1CM8}.
HELIX 156 158 {ECO:0000244|PDB:1CM8}.
STRAND 159 161 {ECO:0000244|PDB:1CM8}.
STRAND 167 169 {ECO:0000244|PDB:1CM8}.
HELIX 189 191 {ECO:0000244|PDB:1CM8}.
HELIX 195 198 {ECO:0000244|PDB:1CM8}.
TURN 199 201 {ECO:0000244|PDB:1CM8}.
HELIX 207 221 {ECO:0000244|PDB:1CM8}.
HELIX 231 242 {ECO:0000244|PDB:1CM8}.
HELIX 247 251 {ECO:0000244|PDB:1CM8}.
HELIX 256 264 {ECO:0000244|PDB:1CM8}.
HELIX 273 275 {ECO:0000244|PDB:1CM8}.
HELIX 282 291 {ECO:0000244|PDB:1CM8}.
TURN 296 298 {ECO:0000244|PDB:1CM8}.
HELIX 302 307 {ECO:0000244|PDB:1CM8}.
HELIX 309 311 {ECO:0000244|PDB:1CM8}.
TURN 312 314 {ECO:0000244|PDB:1CM8}.
HELIX 337 349 {ECO:0000244|PDB:1CM8}.
SEQUENCE 367 AA; 41940 MW; EF680401D8E40610 CRC64;
MSSPPPARSG FYRQEVTKTA WEVRAVYRDL QPVGSGAYGA VCSAVDGRTG AKVAIKKLYR
PFQSELFAKR AYRELRLLKH MRHENVIGLL DVFTPDETLD DFTDFYLVMP FMGTDLGKLM
KHEKLGEDRI QFLVYQMLKG LRYIHAAGII HRDLKPGNLA VNEDCELKIL DFGLARQADS
EMTGYVVTRW YRAPEVILNW MRYTQTVDIW SVGCIMAEMI TGKTLFKGSD HLDQLKEIMK
VTGTPPAEFV QRLQSDEAKN YMKGLPELEK KDFASILTNA SPLAVNLLEK MLVLDAEQRV
TAGEALAHPY FESLHDTEDE PQVQKYDDSF DDVDRTLDEW KRVTYKEVLS FKPPRQLGAR
VSKETPL


Related products :

Catalog number Product name Quantity
EIAAB24867 ERK6,ERK-6,Extracellular signal-regulated kinase 6,Homo sapiens,Human,MAP kinase 12,MAP kinase p38 gamma,MAPK 12,MAPK12,Mitogen-activated protein kinase 12,Mitogen-activated protein kinase p38 gamma,S
EIAAB24866 ERK-6,Extracellular signal-regulated kinase 6,MAP kinase 12,MAP kinase p38 gamma,MAPK 12,Mapk12,Mitogen-activated protein kinase 12,Mitogen-activated protein kinase p38 gamma,Mouse,Mus musculus,Sapk3,
EIAAB24868 ERK-6,Extracellular signal-regulated kinase 6,MAP kinase 12,MAP kinase p38 gamma,MAPK 12,Mapk12,Mitogen-activated protein kinase 12,Mitogen-activated protein kinase p38 gamma,Rat,Rattus norvegicus,Sap
10-782-55059 Mitogen-activated protein kinase 12 - EC 2.7.11.24; Extracellular signal-regulated kinase 6; ERK-6; ERK5; Stress-activated protein kinase 3; Mitogen-activated protein kinase p38 gamma; MAP kinase p38 0.02 mg
10-782-55059 Mitogen-activated protein kinase 12 - EC 2.7.11.24; Extracellular signal-regulated kinase 6; ERK-6; ERK5; Stress-activated protein kinase 3; Mitogen-activated protein kinase p38 gamma; MAP kinase p38 0.001 mg
10-782-55059 Mitogen-activated protein kinase 12 - EC 2.7.11.24; Extracellular signal-regulated kinase 6; ERK-6; ERK5; Stress-activated protein kinase 3; Mitogen-activated protein kinase p38 gamma; MAP kinase p38 0.01 mg
10-782-55060 Mitogen-activated protein kinase 12 - EC 2.7.11.24; Extracellular signal-regulated kinase 6; ERK-6; ERK5; Stress-activated protein kinase 3; Mitogen-activated protein kinase p38 gamma; MAP kinase p38 0.02 mg
10-782-55059 Mitogen-activated protein kinase 12 - EC 2.7.11.24; Extracellular signal-regulated kinase 6; ERK-6; ERK5; Stress-activated protein kinase 3; Mitogen-activated protein kinase p38 gamma; MAP kinase p38 0.005 mg
10-782-55060 Mitogen-activated protein kinase 12 - EC 2.7.11.24; Extracellular signal-regulated kinase 6; ERK-6; ERK5; Stress-activated protein kinase 3; Mitogen-activated protein kinase p38 gamma; MAP kinase p38 0.05 mg
E1206m ELISA kit Erk2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,Mapk,MAPK 1,MAPK 2,Mapk1,Mitogen-activated protein kinase 1,Mitogen-activated protei 96T
E1206r ELISA kit Erk2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,Mapk,MAPK 1,MAPK 2,Mapk1,Mitogen-activated protein kinase 1,Mitogen-activated protei 96T
U1206b CLIA Bos taurus,Bovine,ERK2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAPK 1,MAPK 2,MAPK1,Mitogen-activated protein kinase 1,Mitogen-activated protein kinase 2,PRKM1 96T
E1206b ELISA Bos taurus,Bovine,ERK2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAPK 1,MAPK 2,MAPK1,Mitogen-activated protein kinase 1,Mitogen-activated protein kinase 2,PRKM 96T
E1206b ELISA kit Bos taurus,Bovine,ERK2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAPK 1,MAPK 2,MAPK1,Mitogen-activated protein kinase 1,Mitogen-activated protein kinase 2 96T
U1206r CLIA Erk2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,Mapk,MAPK 1,MAPK 2,Mapk1,Mitogen-activated protein kinase 1,Mitogen-activated protein kina 96T
U1206m CLIA Erk2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,Mapk,MAPK 1,MAPK 2,Mapk1,Mitogen-activated protein kinase 1,Mitogen-activated protein kina 96T
E1206m ELISA Erk2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,Mapk,MAPK 1,MAPK 2,Mapk1,Mitogen-activated protein kinase 1,Mitogen-activated protein kin 96T
E1206r ELISA Erk2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,Mapk,MAPK 1,MAPK 2,Mapk1,Mitogen-activated protein kinase 1,Mitogen-activated protein kin 96T
E1206h ELISA kit ERK2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,Homo sapiens,Human,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,MAPK 1,MAPK 2,MAPK1,Mitogen-activated protein kinase 1,Mitogen-ac 96T
E1206h ELISA ERK2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,Homo sapiens,Human,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,MAPK 1,MAPK 2,MAPK1,Mitogen-activated protein kinase 1,Mitogen-activat 96T
U1206h CLIA ERK2,ERK-2,ERT1,Extracellular signal-regulated kinase 2,Homo sapiens,Human,MAP kinase 1,MAP kinase 2,MAP kinase isoform p42,MAPK 1,MAPK 2,MAPK1,Mitogen-activated protein kinase 1,Mitogen-activate 96T
18-662-20087 Mitogen-activated protein kinase 1 - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 Polyclonal 0.1 ml
15-288-22768 Mitogen-activated protein kinase 1 - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 Polyclonal 0.05 mg
15-288-22768 Mitogen-activated protein kinase 1 - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 Polyclonal 0.1 mg
10-782-55051 Mitogen-activated protein kinase 1 - EC 2.7.11.24; Extracellular signal-regulated kinase 2; ERK-2; Mitogen-activated protein kinase 2; MAP kinase 2; MAPK 2; p42-MAPK; ERT1 N_A 0.05 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur